22 May 2019
Bridging the gap of oral P2Y12 inhibition for PCI with cangrelor: what does the new data tell us?
Sponsored by Chiesi Farmaceutici S.p.A.
Chairpersons:
D. Angiolillo, G. Tarantini
Summary
Consult this session to learn through studies and clinical cases more about contemporary pharmacological strategies with intravenous antiplatelet therapy in PCI for STEMI, NSTEMI and complex stable coronary artery disease patients.
Learning Objectives
- To evaluate current antiplatelet therapy options in interventional cardiology
- To learn more about contemporary pharmacological strategies with intravenous antiplatelet therapy in PCI for STEMI, NSTEMI and complex stable coronary artery disease patients
- To learn more about optimal PCI pharmacological treatment through case discussions
